Efficacy of Thiamine (Vitamin B1) on Post-acute COVID-19 Syndrome: An Open-Label, Randomized, Controlled Trial
| Author | Shabnam Tehrani | en |
| Author | Nastaran Mahmoudnejad | en |
| Author | Amirhossein Ahmadi Asour | en |
| Author | Amirreza Keyvanfar | en |
| Author | Elmira Mahmoudi Chalmiani | en |
| Orcid | Shabnam Tehrani [0000-0001-7005-5398] | en |
| Orcid | Amirreza Keyvanfar [0000-0003-2278-5390] | en |
| Orcid | Elmira Mahmoudi Chalmiani [0009-0009-6094-3979] | en |
| Issued Date | 2024-10-31 | en |
| Abstract | Background: Thiamine (vitamin B1) has the potential to influence the severity of various diseases by enhancing immune function. However, its role in the manifestations of coronavirus disease 2019 (COVID-19) remains inadequately understood. Objectives: This study aimed to investigate the efficacy of thiamine in alleviating symptoms of post-acute COVID-19 syndrome. Methods: In this open-label, randomized, controlled trial, 66 recovered COVID-19 patients experiencing post-acute COVID-19 syndrome were enrolled. Participants were randomly assigned to two groups: An intervention group receiving vitamin B1 alongside supportive therapy and a control group receiving supportive therapy alone. Symptom frequency and severity were monitored weekly over a nine-week period as study outcomes. Data were analyzed using SPSS. Results: The mean age of participants was 49.35 ± 13.83 years. Findings showed that vitamin B1 administration significantly shortened the duration for symptom improvement compared to the control group, with effects observed within two weeks (P < 0.0001). Unlike the control group, many symptoms—including myalgia, anosmia, ageusia, fatigue, and sleep disturbances—showed improvement after five weeks of vitamin B1 supplementation (P < 0.05). From the seventh week onwards, the recovery rate in the vitamin B1 group was twice that of the control group. Conclusions: Our findings indicate that vitamin B1 administration can significantly reduce the duration of post-acute COVID-19 syndrome. For post-acute COVID-19 patients, vitamin B1 supplementation along with appropriate supportive therapy is recommended to enhance recovery rates. | en |
| DOI | https://doi.org/10.5812/archcid-144280 | en |
| Keyword | COVID-19 | en |
| Keyword | Post-acute COVID-19 Syndrome | en |
| Keyword | SARS-CoV-2 | en |
| Keyword | Thiamine | en |
| Keyword | Therapeutics | en |
| Publisher | Brieflands | en |
| Title | Efficacy of Thiamine (Vitamin B1) on Post-acute COVID-19 Syndrome: An Open-Label, Randomized, Controlled Trial | en |
| Type | Research Article | en |
Files
Original bundle
1 - 1 of 1
Loading...
- Name:
- archcid-19-5-144280-publish-pdf.pdf
- Size:
- 518.76 KB
- Format:
- Adobe Portable Document Format
- Description:
- Article/s PDF